Réactivation de tuberculose après traitement immunomodulateur pour une infection sévère à SARS-CoV-2

We report cases of tuberculosis reactivation after COVID-19 treated with corticosteroids and tocilizumab. Both patients had lymphopenia and limited clinical signs. Radiological findings were unusual but microbiological samples were positive. As screening for latent tuberculosis with IGRA seems inapp...

Descripción completa

Detalles Bibliográficos
Autores principales: Garé, Mathilde, Thy, Michael, Deconinck, Laurène, Grall, Nathalie, Yazdanpanah, Yazdan, Joly, Véronique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Société de pathologie infectieuse de langue française (SPILF). Published by Elsevier Masson SAS. 2023
Materias:
Cas Clinique Didactique
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771745/
http://dx.doi.org/10.1016/j.mmifmc.2022.12.003
_version_ 1784854880359284736
author Garé, Mathilde
Thy, Michael
Deconinck, Laurène
Grall, Nathalie
Yazdanpanah, Yazdan
Joly, Véronique
author_facet Garé, Mathilde
Thy, Michael
Deconinck, Laurène
Grall, Nathalie
Yazdanpanah, Yazdan
Joly, Véronique
author_sort Garé, Mathilde
collection PubMed
description We report cases of tuberculosis reactivation after COVID-19 treated with corticosteroids and tocilizumab. Both patients had lymphopenia and limited clinical signs. Radiological findings were unusual but microbiological samples were positive. As screening for latent tuberculosis with IGRA seems inappropriate in this context, latent tuberculosis treatment should be discussed while introducing immunomodulatory treatment for patients at risk.
format Online
Article
Text
id pubmed-9771745
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Société de pathologie infectieuse de langue française (SPILF). Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-97717452022-12-22 Réactivation de tuberculose après traitement immunomodulateur pour une infection sévère à SARS-CoV-2 Garé, Mathilde Thy, Michael Deconinck, Laurène Grall, Nathalie Yazdanpanah, Yazdan Joly, Véronique Médecine et Maladies Infectieuses Formation Cas Clinique Didactique We report cases of tuberculosis reactivation after COVID-19 treated with corticosteroids and tocilizumab. Both patients had lymphopenia and limited clinical signs. Radiological findings were unusual but microbiological samples were positive. As screening for latent tuberculosis with IGRA seems inappropriate in this context, latent tuberculosis treatment should be discussed while introducing immunomodulatory treatment for patients at risk. Société de pathologie infectieuse de langue française (SPILF). Published by Elsevier Masson SAS. 2023-06 2022-12-22 /pmc/articles/PMC9771745/ http://dx.doi.org/10.1016/j.mmifmc.2022.12.003 Text en © 2022 Société de pathologie infectieuse de langue française (SPILF). Published by Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Cas Clinique Didactique
Garé, Mathilde
Thy, Michael
Deconinck, Laurène
Grall, Nathalie
Yazdanpanah, Yazdan
Joly, Véronique
Réactivation de tuberculose après traitement immunomodulateur pour une infection sévère à SARS-CoV-2
title Réactivation de tuberculose après traitement immunomodulateur pour une infection sévère à SARS-CoV-2
title_full Réactivation de tuberculose après traitement immunomodulateur pour une infection sévère à SARS-CoV-2
title_fullStr Réactivation de tuberculose après traitement immunomodulateur pour une infection sévère à SARS-CoV-2
title_full_unstemmed Réactivation de tuberculose après traitement immunomodulateur pour une infection sévère à SARS-CoV-2
title_short Réactivation de tuberculose après traitement immunomodulateur pour une infection sévère à SARS-CoV-2
title_sort réactivation de tuberculose après traitement immunomodulateur pour une infection sévère à sars-cov-2
topic Cas Clinique Didactique
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771745/
http://dx.doi.org/10.1016/j.mmifmc.2022.12.003
work_keys_str_mv AT garemathilde reactivationdetuberculoseaprestraitementimmunomodulateurpouruneinfectionsevereasarscov2
AT thymichael reactivationdetuberculoseaprestraitementimmunomodulateurpouruneinfectionsevereasarscov2
AT deconincklaurene reactivationdetuberculoseaprestraitementimmunomodulateurpouruneinfectionsevereasarscov2
AT grallnathalie reactivationdetuberculoseaprestraitementimmunomodulateurpouruneinfectionsevereasarscov2
AT yazdanpanahyazdan reactivationdetuberculoseaprestraitementimmunomodulateurpouruneinfectionsevereasarscov2
AT jolyveronique reactivationdetuberculoseaprestraitementimmunomodulateurpouruneinfectionsevereasarscov2

Ejemplares similares